Since December 2019, Revive Therapeutics| RVV (CSE) has seen a surge of more than 360% to reach $0.29 / share this week. The reason is simple, Revive entered this promising psychedelic market earlier this year with the acquisition of Psilocin Pharma Corp. Revive is now advancing the development of Psilocybin-based therapeutics in various diseases and disorders.
Psilocin Pharma Corp has developed patent-pending formulation and production solutions for the active compound Psilocybin.
On the top of that, Revive announced they are entering into a sponsored research partnership agreement with the University of Wisconsin-Madison to evaluate novel formulations and drug delivery technology focused on psilocybin-based pharmaceuticals.
They expanded their exclusive license of the drug delivery technology from the Wisconsin Alumni Research Foundation to include all hallucinogenic compounds.
Already a good portfolio of patents
Revive Therapeutics| RVV (CSE) was already in possession of several key licenses in the use of Cannabidiol in the Treatment of Autoimmune Hepatitis with Orphan Drug Designation and key licenses around Cannabinoid Delivery Systems. The company owns the patent for the use of Bucillamine in the Treatment of Gout and already has done a phase 2 study.
Huge market of more than $300 Billion
This market is evaluated by some experts at more than $300 billion calculated from the main markets addressable by psychedelic therapeutics (neurogenics market): mental health drugs, therapy spending, neurodegeneration drugs and cognitive enhancement.
With all these developments, Revive Therapeutics| RVV (CSE) remains one of the most undervalued psychedelic companies versus its peers.
But wait, this company has something more exceptional…
Revive Therapeutics| RVV (CSE) is leveraging its clinical experience with Bucillamine to further initiatives with the drug for the potential treatment of COVID-19 and other infectious diseases. Revive has applied for a provisional patent with the US Patent and Trademark Office entitled “Use of Bucillamine in the Treatment of Infectious Diseases” (Serial No. 62 / 991,996) and the Company is targeting COVID-19 as its lead indication and even did a Phase 2 study in the US under its Investigational New Drug (“IND”) granted by the FDA for the treatment of gout.
On 23th April, Revive Therapeutics| RVV (CSE) announces US FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial to evaluate Bucillamine for the treatment of patients with mild-moderate COVID-19 due to the SARS-CoV-2 infection in order to ensure expeditious evaluation of the safety and efficacy of Bucillamine.
“FDA’s support in advising Revive to move directly into a Phase 3 confirmatory trial provides an acknowledgment for the potential of Bucillamine in the treatment of COVID-19,”
Michael Frank, Chief Executive Officer of Revive commented :
“Entering into a Phase 3 study is a major milestone for the Company, and we are excited to unlock the full potential of Bucillamine not only for this virus but also for other infectious diseases that we will investigate in the future.”
And more, value of Phases through the pipeline
Source : baybridgebio
Revive Therapeutics trades on the CSE with the symbol RVV
VISIT REVIVE THERAPEUTICS PROFILE | HERE
LAST ALERT MADE MORE THAN 360% TO DATE !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.
Disclosure : Revive Therapeutics Ltd is a paid clients of The Cannabis Stock.